Recent studies have suggested that RHOJ is preferentially expressed in epithelial-to-mesenchymal transition cells, with interaction with proteins (FLNB, TLN1 and IPO9) that regulate nuclear actin and inhibit actin polymerization in cancer cells [24]. Here, IPO9 is linked to cancer.